Jubilant Pharmova Limited

NSE JUBLPHARMA.NS

Jubilant Pharmova Limited Shares (Diluted, Weighted) for the year ending March 31, 2024: 158,856,621

Jubilant Pharmova Limited Shares (Diluted, Weighted) is 158,856,621 for the year ending March 31, 2024, a -0.18% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Jubilant Pharmova Limited Shares (Diluted, Weighted) for the year ending March 31, 2023 was 159,147,533, a -0.02% change year over year.
Jubilant Pharmova Limited Shares (Diluted, Weighted) for the year ending March 31, 2022 was 159,173,999, a -0.06% change year over year.
Jubilant Pharmova Limited Shares (Diluted, Weighted) for the year ending March 31, 2021 was 159,266,462, a -0.01% change year over year.
Jubilant Pharmova Limited Shares (Diluted, Weighted) for the year ending March 31, 2020 was 159,278,804, a 0.09% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NSE: JUBLPHARMA.NS

Jubilant Pharmova Limited

CEO	Mr. Priyavrat Bhartia MBA
IPO Date	July 1, 2002
Location	India
Headquarters	1A, Sector 16A
Employees	5,399
Sector	Health Care
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies

Description

Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well as sale of radiopharmaceuticals through a network of 48 radio pharmacies in the United States. The Contract Research & Development Services segment provides collaborative research services to pharmaceutical innovators. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune disorders. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is headquartered in Noida, India.

Key trends

Past 5 years